Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London
November 13, 2018 16:28 ET
|
NOVARTIS FINANCE S.A.
Basel, November 13, 2018 - Novartis today announced that Alcon has filed an initial Form 20-F registration statement with the US Securities and Exchange Commission (SEC) in relation to the...
Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
October 18, 2018 01:02 ET
|
NOVARTIS FINANCE S.A.
Novartis to acquire Endocyte to accelerate development of innovative radioligand technology for treating cancer Acquisition would add 177Lu-PSMA-617, a potential first-in-class radioligand...
Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth
October 18, 2018 01:00 ET
|
NOVARTIS FINANCE S.A.
Net sales grew 6% (cc[1], +3% USD) mainly driven by: Cosentyx grew to USD 750 million (+37% cc) with strong volume growth across indications Entresto more than doubled to USD 271 million...
Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
August 29, 2018 01:00 ET
|
NOVARTIS FINANCE S.A.
Decision based on five-year data from COMPASS-XT long-term safety study Alcon advises ophthalmic surgeons to cease further implantation Basel, August 29, 2018 - Reflecting its uncompromising...
SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
August 23, 2018 01:15 ET
|
NOVARTIS FINANCE S.A.
SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase...
Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
August 14, 2018 01:00 ET
|
NOVARTIS FINANCE S.A.
Basel, August 14, 2018 - Novartis announced today the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and ...
Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)
July 27, 2018 08:53 ET
|
NOVARTIS FINANCE S.A.
Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology Early therapeutic intervention is...
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
July 18, 2018 01:00 ET
|
NOVARTIS FINANCE S.A.
Net sales grew 5% (cc[1], +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD...
Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe
June 29, 2018 08:10 ET
|
NOVARTIS FINANCE S.A.
First CHMP opinion for a CAR-T cell therapy in two distinct indications - DLBCL in adults and B-cell ALL in children Marketing Authorization Application (MAA) based on landmark global CAR-T...
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
June 29, 2018 01:00 ET
|
NOVARTIS FINANCE S.A.
Alcon strategic review concludes that 100% spinoff in best interest of shareholders and consistent with the Novartis strategy of focusing as a medicines company Planned spinoff would create...